In this study, Patients who continued treatment for less than 6 months (38.43%) showed higher baseline AFP, less patients with BCLC-C than B and more prevalent hepatic vein thrombosis, extra-hepatic spread and with significantly worse OS. The gene discussed is AFP; the disease is hepatic vein thrombosis.